Clinical trials: Cholangitis, open to volunteers
Primary Sclerosing Cholangitis
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).
- Trial name
- HAAPS (NCT05295680)
- Testing
- Hymecromone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aparna Goel
Autoimmune Liver Disease, Primary Sclerosing Cholangitis
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Trial name
- NCT03175471
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Biliary Cholangitis
Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis
This phase I/II clinical trial evaluates human umbilical cord-derived mesenchymal stromal cell (hUC-MSC) injection in patients with primary biliary cholangitis (PBC).
- Trial name
- MSC-PBC-I/II (NCT07795151)
- Testing
- Standard background therapy, hUC-MSC Dose Level 1, hUC-MSC Dose Level 2
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Beijing 302 Hospital
Autoimmune Liver Disease, Autoimmune Hepatitis
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- NCT03178630
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Liver Cirrhosis, Hepatocellular Carcinoma (HCC)
A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions
Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis.
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Cholangitis, Sclerosing
- Trial name
- VOCAL2 (NCT06864195)
- Where
- United Kingdom
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Primary Sclerosing Cholangitis, Biliary Atresia
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism.
- Trial name
- NCT02137668
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sacramento Pediatric Gastroenterology
Primary Biliary Cholangitis (PBC)
A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
About 1/3 of patients with primary biliary cholangitis (PBC) exhibit moderate to severe interface hepatitis, and this group of patients have poor response to UDCA treatment.
- Trial name
- NCT06591468
- Testing
- Prednisone, UDCA (Ursodeoxycholic acid)
- Where
- 2 sites in China
- Volunteers
- 244 people
- Sponsor
- Han Ying
Pancreatitis, Acute, Bleeding
Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)
ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla.
- Conditions
- Pancreatitis, Acute, Bleeding, Cholangitis
- Trial name
- SHODBADI (NCT05061680)
- Testing
- endoscopic short duration papillary large balloon dilation
- Where
- 2 sites in Finland
- Volunteers
- 600 people
- Sponsor
- Helsinki University Central Hospital
Fragility, Biliary Obstruction
Sedation Methods in Percutaneous Transhepatic Biliary Drainage: Procedure Quality and Recovery
This prospective, randomized, single-center study aims to evaluate and compare two different sedation and analgesia regimens used during percutaneous transhepatic biliary drainage (PTBD) procedures.
- Conditions
- Fragility, Biliary Obstruction, Cholangitis, Malignancy
- Trial name
- NCT07640243
- Testing
- Remifentanil, Ketamine
- Where
- Turkey (Türkiye)
- Volunteers
- 98 people
- Sponsor
- Ankara City Hospital Bilkent
PSC
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.
- Trial name
- WIND-PSC (NCT06297993)
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 2,000 people
- Sponsor
- PSC Partners Seeking a Cure
Cholecystectomy, Gallbladder
EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study
Cholecystectomy is considered the standard definitive treatment after an acute biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis).
- Conditions
- Cholecystectomy, Gallbladder, Endoscopic Ultrasound (EUS), Cholelithiasis
- Trial name
- DRECON (NCT07655778)
- Testing
- EUS-guided gallbladder drainage (EUS-GBD), Conservative management (CM)
- Volunteers
- 110 people
- Sponsor
- Hospital Mutua de Terrassa
Primary Biliary Cholangitis
Monitoring the Response of Combination Ursodiol and Seladelpar Treatment
This study aims to provide comprehensive insights into the therapeutic effects of combination treatment with ursodiol and seladelpar in PBC patients by assessing biochemical responses using biomarkers such as ALP and total…
- Trial name
- NCT07122206
- Testing
- Blood Draws
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Cholangiocarcinoma, Pancreatic Cancer
Registry for Advanced Endoscopy
Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Sclerosing Cholangitis
- Trial name
- ERDB (NCT05187312)
- Testing
- Endoscopic retrograde Cholangio- pancreatography, Endoscopic ultrasound
- Where
- Sweden
- Volunteers
- 1,000 people
- Sponsor
- Region Stockholm
Primary Biliary Cholangitis (PBC)
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
The purpose of this study is to understand how tiredness changes in adults with Primary Biliary Cholangitis (PBC) after starting elafibranor in routine clinical practice.
- Trial name
- NCT07906639
- Testing
- Elafibranor
- Volunteers
- 50 people
- Sponsor
- Ipsen
Primary Biliary Cholangitis
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid…
- Trial name
- NCT07282353
- Testing
- 2mg CS0159
- Where
- 42 sites in China
- Volunteers
- 135 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Primary Biliary Cholangitis
Clinical Research of Tapering UDCA in PBC Patients With a Complete Response
This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis.
- Trial name
- UDCA PBC (NCT04650243)
- Testing
- ursodeoxycholic acid
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Primary Biliary Cholangitis
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
Long-Term Study to Evaluate the Safety and Efficacy in Participants with Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (EPICS-V)
- Trial name
- EPICS-V (NCT07216235)
- Testing
- Saroglitazar magnesium 1 mg
- Where
- 3 sites in United States
- Volunteers
- 386 people
- Sponsor
- Zydus Therapeutics Inc.
Healthy Volunteers, Primary Sclerosing Cholangitis
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
The main aim of this study is to see if the drug TAK-781 is safe for healthy volunteers and for participants with PSC. The study will also look at how well participants can tolerate TAK-781.
- Trial name
- NCT07229911
- Testing
- TAK-781
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Takeda
Primary Sclerosing Cholangitis, Liver Diseases
Primary Sclerosing Cholangitis in Children
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine.
- Conditions
- Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
- Trial name
- NCT04181138
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Arbor Research Collaborative for Health